the approval of yescarta brings this innovative class of car-t cell therapies to an additional group of cancer patients with few other options – those adults with certain types of lymphoma that have not responded to previous treatments , ” said peter marks , m.d. newline_char the u.s. food and drug administration today approved yescarta ( axicabtagene ciloleucel ) , a cell-based gene therapy , to treat adult patients with certain types of large b-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment . newline_char each dose of yescarta is a customized treatment created using a patient ’ s own immune system to help fight the lymphoma . newline_char yescarta , a chimeric antigen receptor ( car ) t cell therapy , is the second gene therapy approved by the fda and the first for certain types of non-hodgkin lymphoma ( nhl ) . newline_char yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma . story_separator_special_tag " louis degennaro , the chief executive of the leukemia and lymphoma society , which helped fund yescarta 's development , wrote in an email blast that " many patients who were out of treatment options are now in remission " because of experimental studies of the drug . newline_char but the treatment feldman received was just approved by the food and drug administration under the brand name yescarta , with a bracing price tag : $ 373,000 per patient . newline_char fda commissioner scott gottlieb , himself a cancer survivor , called yescarta " another milestone in the development of a whole new scientific paradigm . newline_char yescarta is the second treatment of its kind , called a chimeric antigen receptor t-cell , or car-t , for the particular genetic modifications made to white cells .
